Trial Profile
Prospective Single Arm Post Marketing Phase IV Study to Assess the Safety and Efficacy of Lenvatinib in Subjects With Locally Recurrent or Metastatic, Progressive, Radioiodine Refractory Differentiated Thyroid Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 05 Jul 2023
Price :
$35
*
At a glance
- Drugs Lenvatinib (Primary)
- Indications Thyroid cancer
- Focus Adverse reactions
- Sponsors Eisai Co Ltd; Eisai Inc; Eisai Pharmaceuticals India Pvt. Ltd
- 29 Jun 2023 Planned End Date changed from 31 Dec 2022 to 1 May 2024.
- 29 Jun 2023 Planned primary completion date changed from 31 Dec 2022 to 1 May 2024.
- 09 Dec 2021 Planned End Date changed from 20 Mar 2021 to 31 Dec 2022.